Sarepta Therapeutics (SRPT) Downgraded to Hold at BidaskClub

Sarepta Therapeutics (NASDAQ:SRPT) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued on Saturday.

Other equities research analysts have also issued research reports about the stock. Robert W. Baird reissued a “buy” rating and set a $101.00 price objective on shares of Sarepta Therapeutics in a research note on Tuesday, October 17th. Oppenheimer reissued a “buy” rating and set a $76.00 price objective on shares of Sarepta Therapeutics in a research note on Monday, October 16th. Janney Montgomery Scott initiated coverage on shares of Sarepta Therapeutics in a research note on Wednesday, January 3rd. They set a “buy” rating and a $75.00 price objective on the stock. HC Wainwright set a $75.00 price objective on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, January 3rd. Finally, Zacks Investment Research raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating and set a $54.00 price objective on the stock in a research note on Monday, October 30th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating and seventeen have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $64.65.

Shares of Sarepta Therapeutics (NASDAQ SRPT) opened at $55.14 on Friday. Sarepta Therapeutics has a 52 week low of $26.26 and a 52 week high of $68.90. The company has a debt-to-equity ratio of 0.04, a quick ratio of 9.52 and a current ratio of 10.44. The company has a market cap of $3,440.00, a PE ratio of -27.03 and a beta of 1.49.

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 6,667 shares of Sarepta Therapeutics stock in a transaction dated Thursday, November 30th. The shares were sold at an average price of $55.89, for a total value of $372,618.63. Following the completion of the transaction, the director now directly owns 13,333 shares of the company’s stock, valued at $745,181.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 9.60% of the stock is currently owned by insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. 361 Capital LLC purchased a new position in shares of Sarepta Therapeutics during the third quarter valued at approximately $1,914,000. Janney Montgomery Scott LLC purchased a new position in shares of Sarepta Therapeutics during the third quarter valued at approximately $474,000. Hikari Power Ltd purchased a new position in shares of Sarepta Therapeutics during the third quarter valued at approximately $1,134,000. Oppenheimer & Co. Inc. raised its holdings in shares of Sarepta Therapeutics by 53.0% during the third quarter. Oppenheimer & Co. Inc. now owns 33,592 shares of the biotechnology company’s stock valued at $1,524,000 after purchasing an additional 11,639 shares during the last quarter. Finally, Jennison Associates LLC raised its holdings in shares of Sarepta Therapeutics by 0.6% during the fourth quarter. Jennison Associates LLC now owns 1,150,210 shares of the biotechnology company’s stock valued at $63,998,000 after purchasing an additional 6,357 shares during the last quarter. 81.97% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2018/02/10/sarepta-therapeutics-srpt-downgraded-to-hold-at-bidaskclub.html.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply